Great Lakes Advisors LLC Has $12.29 Million Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

Great Lakes Advisors LLC lessened its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 3.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,015,038 shares of the company's stock after selling 40,104 shares during the quarter. Great Lakes Advisors LLC owned about 0.21% of Elanco Animal Health worth $12,292,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in ELAN. AM Squared Ltd acquired a new position in shares of Elanco Animal Health during the third quarter valued at $34,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Elanco Animal Health during the third quarter valued at $35,000. Farther Finance Advisors LLC lifted its stake in shares of Elanco Animal Health by 158.7% during the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company's stock valued at $49,000 after acquiring an additional 2,044 shares during the period. Venturi Wealth Management LLC lifted its stake in shares of Elanco Animal Health by 89.9% during the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company's stock valued at $50,000 after acquiring an additional 1,601 shares during the period. Finally, Jones Financial Companies Lllp lifted its stake in shares of Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after acquiring an additional 2,059 shares during the period. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Stock Up 1.5 %

Shares of NYSE ELAN traded up $0.16 during mid-day trading on Friday, reaching $10.47. 4,680,857 shares of the company's stock were exchanged, compared to its average volume of 4,674,860. The firm has a market capitalization of $5.18 billion, a price-to-earnings ratio of 26.16, a PEG ratio of 2.50 and a beta of 1.44. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The business has a fifty day simple moving average of $11.46 and a 200 day simple moving average of $12.75. Elanco Animal Health Incorporated has a twelve month low of $10.03 and a twelve month high of $18.80.

Remove Ads

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company's revenue for the quarter was down 1.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.08 EPS. As a group, equities analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ELAN shares. Leerink Partnrs raised Elanco Animal Health to a "hold" rating in a research note on Monday, December 2nd. UBS Group cut their target price on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Morgan Stanley cut their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 26th. Piper Sandler cut their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Finally, Barclays cut their target price on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health has an average rating of "Hold" and a consensus target price of $15.17.

Insider Buying and Selling

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of the firm's stock in a transaction on Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the purchase, the director now directly owns 111,459 shares in the company, valued at $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.57% of the stock is owned by corporate insiders.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.